<DOC>
	<DOCNO>NCT02859415</DOCNO>
	<brief_summary>Background : Mithramycin new cancer drug . In another study , people chest cancer take drug 6 hour day 7 straight day . Many liver damage side effect . It discover people certain gene get side effect . Researchers want test mithramycin people certain gene . &lt; TAB &gt; Objectives : To find high safe dose mithramycin give people chest cancer certain gene 24 hour instead spread long period time . To see mithramycin give 24-hour infusion shrink tumor . Eligibility : People age 18 old chest cancer shrink know therapy , whose gene limit chance liver damage mithramycin Design : Participants screen : Medical history Physical exam Blood urine test Lung heart function test X-rays scan tumor Liver ultrasound Tumor biopsy Participants admit hospital overnight . A small plastic tube ( catheter ) insert arm chest . They get mithramycin catheter 24 hour . If bad side effect cancer worsen , repeat treatment every 14 day . Participants multiple visit treatment cycle . These include repeat certain screening test . After stop treatment , participant weekly visit recover side effect .</brief_summary>
	<brief_title>Continuous 24h Intravenous Infusion Mithramycin , Inhibitor Cancer Stem Cell Signaling , People With Primary Thoracic Malignancies Carcinomas , Sarcomas Germ Cell Neoplasms With Pleuropulmonary Metastases</brief_title>
	<detailed_description>Background : Increasing evidence indicate activation stem cell gene expression common mechanism environmental carcinogen mediate initiation progression thoracic malignancy . Similar mechanism appear contribute extra-thoracic malignancy metastasize chest . Utilization pharmacologic agent , target gene regulatory network mediate stemness may novel strategy treatment neoplasms . Recent study perform Thoracic Epigenetics Laboratory , TGIB/NCI , demonstrate exposure condition potentially achievable clinical setting , mithramycin diminishes stem cell gene expression markedly inhibit growth lung esophageal cancer malignant pleural mesothelioma ( MPM ) cell vitro vivo . These finding add recent preclinical study demonstrate impressive anti-tumor activity mithramycin epithelial malignancy sarcomas frequently metastasize thorax . Primary Objectives : - Phase I component : To determine pharmacokinetics , toxicity , maximum tolerate dose ( MTD ) mithramycin administer continuous 24hr infusion patient primary thoracic malignancy carcinomas , sarcomas germ cell tumor metastatic chest . - Phase II component : To determine objective response rate ( CR+PR ) mithramycin administer 24h intravenous infusion patient primary thoracic malignancy carcinomas , sarcomas germ cell tumor metastatic chest . Eligibility : - Patients histologically cytologically proven primary malignancy involve lung , esophagus , thymus , pleura , chest wall mediastinum , extra-thoracic malignancy metastatic chest . - Patients germline SNPs ABCB4 ABCB11 associate resistance mithramycin-induced hepatotoxicity . - Patients must refuse first-line standard therapy malignancy . - Patients must 18 year old ECOG performance status 0-2 , without evidence unstable decompensated myocardial disease . Patients must adequate pulmonary reserve evidence FEV1 DLCO equal great 30 % predict ; pCO2 less 55 mm Hg pO ( 2 ) great equal 60 mm Hg room air ABG . - Patients must platelet count great equal 100,000 , ANC equal great 1500 without transfusion cytokine support , normal PT , adequate hepatic function evidence total bilirubin &lt; 1.5 time upper limit normal . Serum creatinine within normal institutional limit creatinine clearance great equal 60 mL/min/1.73 ( 2 ) patient creatinine level institutional normal Design : - Single arm Phase I dose escalation define pharmacokinetics , toxicity MTD . - Patient cohort receive 24h infusion mithramycin target total dos currently administer 7 daily six hour infusion 30-50mcg/kg . - The 24 h infusion administer every 14 day ( 1 cycle ) . Four cycle constitute one course therapy . - Pharmacokinetics toxicity assessment define MTD assess cycle 1 first course therapy . - Due uncertainty regard potential cumulative toxicity , intra-patient dose escalation allow . - Once MTD define , patient stratify two cohort ( primary thoracic malignancy v neoplasm non-thoracic origin metastatic chest ) determine clinical response rate MTD , use Simon Optimal Two Stage Design Phase II Clinical Trials target objective response rate ( RECIST ) 30 % . - Following course therapy , patient undergo restaging study . Patients exhibit objective response therapy stable disease RECIST criterion offer additional course therapy . - Patients exhibit disease progression remove study . - Biopsies index lesion obtain baseline day 4 first feasible second cycle therapy analysis pharmacodynamic endpoint . An additional biopsy may request patient exhibit objective response follow one course therapy .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Thymus Neoplasms</mesh_term>
	<mesh_term>Thymoma</mesh_term>
	<mesh_term>Plicamycin</mesh_term>
	<criteria>INCLUSION CRITERIA : Diagnosis : Patients measurable inoperable , histologically confirm nonsmall cell lung cancer ( NSCLC ) , small cell lung cancer ( SCLC ) , esophageal carcinoma , thymic epithelial neoplasm , germ cell tumor , malignant pleural mesothelioma chest wall sarcoma , well patient gastric , colorectal , pancreas renal cancer , germ cell tumor sarcomas metastatic thorax eligible . Histologic confirmation disease Laboratory Pathology , CCR , NCI , NIH . Germline ABCB4 ( CC ) ABCB11 ( GG GC ) genotype determine pharmacogenomics analysis peripheral blood mononuclear cell . Disease amenable biopsy via percutaneous approach minimally invasive procedure thoracoscopy , bronchoscopy , laparoscopy , GI endoscopy Age great equal to18 ECOG status 02 Patients must , refuse firstline standard chemotherapy inoperable malignancy . Patients must chemotherapy , biologic therapy , radiation therapy malignancy least 30 day prior treatment . Patients may receive localized radiation therapy nontarget lesion provide radiotherapy complete 14 day prior commence therapy , patient recover toxicity . At least 3 halflives must elapse since monoclonal antibody treatment . At least six week must elapse mitomycin C nitrosourea treatment . Patients must adequate organ marrow function define : 1 . Hematologic Coagulation Parameters : Peripheral ANC great equal 1500/mm ( 3 ) Platelets great equal 100,000/ mm ( 3 ) ( transfusion independent ) Hemoglobin great equal 8 g/dL ( PRBC transfusion permit ) PT/PTT within normal limit ( 11.6 15.2 / 25.3 37.3 sec ) 2 . Hepatic Function Bilirubin ( total ) &lt; 1.5 time upper limit normal ( ULN ) ALT ( SGPT ) less equal 3.0 time ULN Albumin &gt; 2 g/dL 3 . Renal Function Creatinine within normal institutional limit creatinine clearance great equal 60 mL/min/1.73 ( 2 ) patient creatinine level institutional normal . Normal ionized calcium , magnesium phosphorus ( oral supplementation ) Cardiac Function : Left ventricular ejection fraction ( EF ) &gt; 40 % echocardiogram , MUGA , cardiac MR. Ability subject understand , willing sign inform consent Female male patient ( relevant partner ) must willing practice birth control ( include abstinence ) two month treatment female childbearing potential male sexual contact female childbearing potential . Patients must willing undergo 2 tumor biopsy EXCLUSION CRITERIA : Clinically significant systemic illness ( e.g . serious active infection significant cardiac , pulmonary , hepatic organ dysfunction ) , judgment PI would compromise patient ability tolerate protocol therapy significantly increase risk complication Patients cerebral metastasis Patients follow pulmonary function abnormality exclude : FEV , &lt; 30 % predict ; DLCO , &lt; 30 % predict ( postbronchodilator ) ; pO2 &lt; 60 mm Hg pCO2 great equal 55 mm Hg room air arterial blood gas . Patients evidence active bleeding , intratumoral hemorrhage history bleeding diatheses , unless specifically occur isolate incident reversible chemotherapyinduced thrombocytopenia Patients therapeutic anticoagulation Note : prophylactic anticoagulation ( i.e . intralumenal heparin ) venous arterial access device allow . Patients concurrently receive require follow agent , may increase risk mithramycin related toxicity , hemorrhage : Thrombolytic agent Aspirin salicylatecontaining product , may increase risk hemorrhage Dextran Dipyridamole Sulfinpyrazone Valproic acid Clopidogrel Lactating pregnant female ( due risk fetus newborn , lack test excretion breast milk ) . Patients history HIV , HBV HCV due potentially increase risk mithramycin toxicity population . Hypersensitivity mithramycin Patients opinion investigator may able comply safety monitoring requirement study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>March 28, 2017</verification_date>
	<keyword>Metastatic Colorectal Cancer</keyword>
	<keyword>Metastatic Renal Cell Cancer</keyword>
	<keyword>Sarcoma</keyword>
	<keyword>ABCB4 Liver Toxicity</keyword>
	<keyword>ABCB11 Heptatoxicity</keyword>
</DOC>